New study tests paliperidone for schizophrenia in bangladesh
NCT ID NCT07153835
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study will test the safety and effectiveness of an extended-release medication called paliperidone in 505 adults with schizophrenia in Bangladesh. Participants will take the medication for 12 weeks, and researchers will track changes in symptoms, side effects, and quality of life. The goal is to see if this treatment helps control the condition better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sher-E-Bangla Medical College Hospital
Barishal, 8200, Bangladesh
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.